Gene therapy data weigh on Ultragenyx shares

Ultragenyx shed more than $350 million in market cap on Wednesday as investors digested additional data from a Phase I/II trial of gene therapy DTX401 for glycogen storage disease and news that the company would add more patients to the trial to confirm the dose.

Data from

Read the full 465 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE